title: Investigation into withdrawal of entecavir after 20 months in an HBsAb-positive patient who received HBsAg allogeneic stem cell transplantation.
abstract: Hepatitis B virus (HBV) infection of donors and recipients is not an absolute contraindication for allogeneic stem cell transplantation (allo-HSCT). We studied a patient who received allo-HSCT from an HBsAg-positive donor. The patient was administered long-term immunosuppressive therapy and treated with the oral anti-viral medication, entecavir (ETV). During this treatment, there was no hepatitis B activity, which suggested that the treatment could effectively prevent the incidence of activated hepatitis. HBsAb was detected prior to stopping treatment with ETV, and hepatitis B activity occurred after stopping ETV. This suggested that the recipient was HBsAb-positive before transplantation, with the use of strong immunosuppressive agents, it is possible that HBV infection could occur after stopping ETV treatment because of reactivation of a latent HBV infection or receiving an allo-HSCT from HBsAg-positive donors. The recipient of an allo-HSCT from an HBsAg-positive donor should be given preventive anti-HBV medication when they receive long-term immunosuppressive therapy.
authors.affiliation: Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: J
authors.initials: J
authors.lastname: Peng
authors.affiliation: Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: W F
authors.initials: WF
authors.lastname: Luo
authors.affiliation: Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: B
authors.initials: B
authors.lastname: Zhou
authors.affiliation: Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: W Q
authors.initials: WQ
authors.lastname: Wen
mesh_terms: D000328:Adult; D005260:Female; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006509:Hepatitis B / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000187:drug effects / Q000276:immunology*; D006515:Hepatitis B virus / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D007165:Immunosuppression Therapy; D056737:Safety-Based Drug Withdrawals; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014019:Tissue Donors; D066027:Transplant Recipients; D014184:Transplantation, Homologous / Q000009:adverse effects*
chemical_list: D006514:Hepatitis B Surface Antigens; C413685:entecavir; D006147:Guanine